SCHEMBL29455720

SCHEMBL29455720

Cc1ccc(S(=O)(=O)n2ccc3c(-c4ccc5cc(Br)ccc5n4)cn(C)c(=O)c32)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 7/20 0.65
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ NPSR1 Q6W5P4 3/20 0.33
▸ RXFP1 Q9HBX9 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ TP53 P04637 2/20 0.33
▸ PPARG P37231 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NR2E3 Q9Y5X4 1/20 0.33
▸ NCOR2 Q9Y618 1/20 0.33
▸ MEN1 O00255 3/20 0.32
▸ KMT2A Q03164 3/20 0.32
▸ PKM P14618 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ NCOA2 Q15596 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29455742 0.90 BRD4 (0.53) BRD4L3MBTL1CA1CA2NPSR1
SCHEMBL29455793 0.87 BRD4 (0.50) BRD4L3MBTL1CA1CA2NPSR1
SCHEMBL29455873 0.83 BRD4 (0.45) BRD4L3MBTL1CA1CA2NPSR1
SCHEMBL29455988 0.83 BRD4 (0.57) BRD4L3MBTL1
SCHEMBL29455977 0.80 BRD4 (0.54) BRD4
SCHEMBL29455964 0.78 BRD4 (0.54) BRD4L3MBTL1
SCHEMBL15069300 0.78 BRD4 (0.54) BRD4CA1CA2MAPTKDM4E
SCHEMBL29455769 0.77 BRD4 (0.55) BRD4L3MBTL1RXFP1MAPTSMN1; SMN2
SCHEMBL29455859 0.76 BRD4 (0.55) BRD4L3MBTL1PKMLMNAALDH1A1
SCHEMBL31590455 0.76 BRD4 (0.58) BRD4L3MBTL1CA1CA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 — — US disclosed
US-20220079951-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD SAINT LOUIS UNIVERSITY (US) 2022-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220079951-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD BRDT, PHKB, BET1 BRD4 4/4885L3MBTL1 2448/4885CA1 4792/4885
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD BRDT, BET1, PHKB BRD4 6/4885L3MBTL1 920/4885CA1 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback